| Date Filed | Type | Description |
| 05/30/2023 |
4
| Katkin Keith (Director) has filed a Form 4 on Emergent BioSolutions Inc.|
Txns:
| Granted 33,847 shares
@ $0 |
|
| 05/02/2023 |
4
| Katkin Keith (Director) has filed a Form 4 on Eledon Pharmaceuticals, Inc.|
Txns:
| Granted 752,185 options to buy
@ $2.3, valued at
$1.7M
|
|
| 02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/02/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/07/2022 |
4
| Katkin Keith (Director) has filed a Form 4 on Syndax Pharmaceuticals Inc|
Txns:
| Sold 20,782 shares
@ $25.9009, valued at
$538.3k
Sold 9,117 shares
@ $25.9009, valued at
$236.1k
Exercised 9,117 options to buy
@ $8.93, valued at
$81.4k
Exercised 20,782 options to buy
@ $7.88, valued at
$163.8k
|
|
| 10/04/2022 |
4
| Katkin Keith (Director) has filed a Form 4 on Syndax Pharmaceuticals Inc|
Txns:
| Sold 2,914 shares
@ $25.0707, valued at
$73.1k
Sold 647 shares
@ $25.0707, valued at
$16.2k
Sold 167 shares
@ $25, valued at
$4.2k
Sold 13 shares
@ $25, valued at
$325
Sold 137 shares
@ $25, valued at
$3.4k
Sold 223 shares
@ $25, valued at
$5.6k
Exercised 647 options to buy
@ $8.93, valued at
$5.8k
Exercised 2,914 options to buy
@ $7.88, valued at
$23k
Exercised 13 options to buy
@ $8.93, valued at
$116.1
Exercised 167 options to buy
@ $7.88, valued at
$1.3k
Exercised 223 options to buy
@ $8.93, valued at
$2k
|
|
| 04/05/2022 |
4
| Katkin Keith (Director) has filed a Form 4 on Emergent BioSolutions Inc.|
Txns:
| Granted 8,595 shares
@ $0 |
|
| 04/05/2022 |
3
| Katkin Keith (Director) has filed a Form 3 on Emergent BioSolutions Inc. |
| 02/03/2022 |
4
| Katkin Keith (Director) has filed a Form 4 on Syndax Pharmaceuticals Inc|
Txns:
| Granted 16,000 shares
@ $0 |
|
| 02/02/2022 |
4
| Katkin Keith (Director) has filed a Form 4 on Eledon Pharmaceuticals, Inc.|
Txns:
| Granted 20,000 options to buy
@ $3.97, valued at
$79.4k
|
|
| 05/21/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/05/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/15/2020 |
4
| Katkin Keith (Director) has filed a Form 4 on Novus Therapeutics, Inc.|
Txns:
| Granted 5,907 options to buy
@ $500, valued at
$3M
|
|
| 05/15/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/21/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/14/2020 |
4
| Katkin Keith (Director) has filed a Form 4 on Syndax Pharmaceuticals Inc|
Txns:
| Granted 24,000 options to buy
@ $9.47, valued at
$227.3k
|
|
| 01/09/2020 |
4
| Katkin Keith (PEO;CEO/Urovant Sciences, Inc.) has filed a Form 4 on Urovant Sciences Ltd.|
Txns:
| Granted 199,680 shares
@ $0 |
|
| 12/11/2019 |
4
| Katkin Keith (PEO;CEO/Urovant Sciences, Inc.) has filed a Form 4 on Urovant Sciences Ltd.|
Txns:
| Sold 120,000 shares
@ $12.78, valued at
$1.5M
Exercised 120,000 options to buy
@ $3.86, valued at
$463.2k
|
|
| 07/15/2019 |
4
| Katkin Keith (Director) has filed a Form 4 on Novus Therapeutics, Inc.|
Txns:
| Granted 20,000 options to buy
@ $0.88, valued at
$17.6k
|
|
| 06/12/2019 |
4
| Katkin Keith (Director) has filed a Form 4 on Syndax Pharmaceuticals Inc|
Txns:
| Granted 24,000 options to buy
@ $7.88, valued at
$189.1k
|
|
| 05/24/2019 |
4
| Katkin Keith (Director) has filed a Form 4 on RIGEL PHARMACEUTICALS INC|
Txns:
| Granted 55,000 options to buy
@ $2.02, valued at
$111.1k
|
|
| 01/08/2019 |
4
| Katkin Keith (PEO;CEO/Urovant Sciences, Inc.) has filed a Form 4 on Urovant Sciences Ltd.|
Txns:
| Granted 350,250 options to buy
@ $6.88, valued at
$2.4M
|
|
| 10/17/2018 |
4
| Katkin Keith (PEO;CEO-Urovant Sciences,Inc.) has filed a Form 4 on Urovant Sciences Ltd.|
Txns:
| Granted 99,967 options to buy
@ $13.65, valued at
$1.4M
|
|
| 10/03/2018 |
4
| Katkin Keith (PEO;CEO-Urovant Sciences,Inc.) has filed a Form 4 on Urovant Sciences Ltd.|
Txns:
| Granted 200,250 options to buy
@ $0 |
|
| 09/28/2018 |
4
| Katkin Keith (PEO;CEO-Urovant Sciences,Inc.) has filed a Form 4 on Urovant Sciences Ltd.|
Txns:
| Granted 39,815 options to buy
@ $14, valued at
$557.4k
|
|
| 09/26/2018 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 06/14/2018 |
4
| Katkin Keith (Director) has filed a Form 4 on Novus Therapeutics, Inc.|
Txns:
| Granted 9,100 options to buy
@ $6.18, valued at
$56.2k
|
|
| 05/25/2018 |
4
| Katkin Keith (Director) has filed a Form 4 on Syndax Pharmaceuticals Inc|
Txns:
| Granted 14,000 options to buy
@ $8.93, valued at
$125k
|
|
| 05/18/2018 |
4
| Katkin Keith (Director) has filed a Form 4 on RIGEL PHARMACEUTICALS INC|
Txns:
| Granted 40,000 options to buy
@ $3.98, valued at
$159.2k
|
|
| 02/12/2018 |
4
| Katkin Keith (Director) has filed a Form 4 on Syndax Pharmaceuticals Inc|
Txns:
| Granted 10,000 options to buy
@ $9.63, valued at
$96.3k
|
|
| 07/05/2017 |
4
| Katkin Keith (Director) has filed a Form 4 on Novus Therapeutics, Inc.|
Txns:
| Granted 36,000 options to buy
@ $5.85, valued at
$210.6k
|
|
| 05/12/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 05/11/2017 |
3
| Katkin Keith (Director) has filed a Form 3 on Novus Therapeutics, Inc. |
| 03/31/2017 |
4
| Katkin Keith (Director) has filed a Form 4 on Syndax Pharmaceuticals Inc |
|